Clinical trial
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in…
NCT00310531 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00310531 |
|---|---|
| Title | 3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women |
| Official title | A Multicenter, Double-Blind, Double-Dummy, Randomized, Active- Controlled, 3-Year Study to Evaluate the Antiresorptive Efficacy, Safety and Tolerability of a Ultra-Low Dose Estradiol Transdermal Delivery System Releasing 0.014 mg / Day Versus Oral Raloxifene Hydrochloride 60 mg / Day - as a Therapy… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteopenia |
| Intervention type | Drug |
| Interventions | Menostar (Estradiol, BAY86-5435), Raloxifene |
| Enrollment | 500 |
| Start date | Feb 1, 2004 |
| Completion | Jun 1, 2007 |
| First posted | Apr 4, 2006 |
| Last update posted | Dec 30, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: